<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02713763</url>
  </required_header>
  <id_info>
    <org_study_id>GETNE-2016-01</org_study_id>
    <secondary_id>2015-005774-37</secondary_id>
    <nct_id>NCT02713763</nct_id>
  </id_info>
  <brief_title>Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib</brief_title>
  <acronym>RESUNET</acronym>
  <official_title>Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated G1/2 Advanced or Metastatic Who Previously Failed to Sunitinib.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol de Tumores Neuroendocrinos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apices Soluciones S.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Grupo Espanol de Tumores Neuroendocrinos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The therapeutic goals in the management of pancreatic neuroendocrine tumors (pNET) are the&#xD;
      control of symptoms and tumor growth control in order to improve patient survival.&#xD;
&#xD;
      In recent years, data from two phase III studies with targeted therapies, sunitinib and&#xD;
      everolimus, have broadened the possibilities for treatment of patients with neuroendocrine&#xD;
      tumors of the pancreas.&#xD;
&#xD;
      Unfortunately, patients progress and development of new active drugs and evaluating the best&#xD;
      treatment approach is decisive.&#xD;
&#xD;
      Given the lack of data comparing the activity of different treatment strategies, final&#xD;
      decisions are based on medical experience and consensus of experts. In this context,&#xD;
      different questions are still unanswered, as which is the best sequence of treatment and if&#xD;
      all patients can benefit from all available drugs.&#xD;
&#xD;
      Neuroendocrine pancreatic tumors are highly vascularized tumors in which cells may be&#xD;
      dependent on this pathway for growth throughout the entire history of the tumor and in which&#xD;
      inhibition of this pathway is crucial. On the other hand, this aspect has not been endorsed&#xD;
      by the population of patients with pNET who have previously failed treatment with sunitinib.&#xD;
&#xD;
      In this scenario the investigators will assess retreatment with sunitinib to evaluate the&#xD;
      activity of this drug in the context of therapeutic rescue in patients with metastatic pNET.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">October 23, 2019</completion_date>
  <primary_completion_date type="Actual">October 23, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months progression free survival</measure>
    <time_frame>6 months</time_frame>
    <description>Time form start of treatment to progression disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>Time form start of treatment to death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Time form start of treatment to progression disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response duration</measure>
    <time_frame>12 months</time_frame>
    <description>Time from first response to progression disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Complete response + partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Number of adverse events per patient</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Pancreatic Neuroendocrine Tumour Metastatic</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sunitinib 37.5 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>Sunitinib 37.5 mg/day</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects &gt; 18 years old and able to give their informed consent.&#xD;
&#xD;
          -  Patients diagnosed with Neuroendocrine Tumor of pancreatic origin and histologically&#xD;
             confirmed, G1/2 according to the World Health Organization (WHO) classification (Ki67&#xD;
             &lt;20% and/or mitotic count &gt;20 mitoses x 10 HPF).&#xD;
&#xD;
          -  Metastatic disease progression in the 12 months prior to baseline visit documented by&#xD;
             CT, MRI or Octreoscan.&#xD;
&#xD;
          -  Progression to prior treatment with sunitinib administered for metastatic disease and&#xD;
             have received at least 1 line and no more than 2 lines of subsequent systemic&#xD;
             treatment.&#xD;
&#xD;
          -  Measurable disease according to the following criteria RECIST version 1.1&#xD;
&#xD;
          -  No disease that can be treated with surgery, radiotherapy or combined treatment with&#xD;
             curative intent.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-2.&#xD;
&#xD;
          -  Pretreatment with somatostatin analogues, chemotherapy, anti-VEGF (vascular&#xD;
             endothelial growth factor) and mTOR (mammalian target of rapamycin) inhibitors prior&#xD;
             to participation in the study is allowed.&#xD;
&#xD;
          -  Adequately controlled blood pressure (BP) &lt;150/90 mmHg.&#xD;
&#xD;
          -  Hematologic Function: - Absolute neutrophil count &gt;1500 / microliter (uL) - Platelets&#xD;
             &gt;100,000 / uL - Hemoglobin &gt;5.6 mmol / L (9 g / dL)&#xD;
&#xD;
          -  Liver function: total bilirubin &lt; 1.5 x upper limit of normal (ULN), unless&#xD;
             unconjugated hyperbilirubinemia or Gilbert syndrome. - Alanine aminotransferase (ALT)&#xD;
             or aspartate aminotransferase (AST) &lt; 2.5 x ULN (&lt; 5 times in case of liver&#xD;
             metastases).&#xD;
&#xD;
          -  Renal function: calculated creatinine clearance according to Cockcroft-Gault &gt; 30 ml /&#xD;
             min.&#xD;
&#xD;
          -  Blood coagulation: prothrombin time (PT) or International Normalized Ratio (INR) &lt; 1.2&#xD;
             x ULN.&#xD;
&#xD;
          -  Proteinuria &lt;2+ urine dipstick. If &gt; 2+ proteinuria, urinary protein &lt;1 g / 24 h.&#xD;
&#xD;
          -  Life expectancy&gt; 3 months.&#xD;
&#xD;
          -  Patient able to swallow the study drug and comply with the monitoring requirements of&#xD;
             the study. - Women of childbearing potential must present a negative pregnancy test.&#xD;
             Women of childbearing potential must agree to use contraception.&#xD;
&#xD;
          -  Men whose partners are women of childbearing potential must use effective&#xD;
             contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neuroendocrine tumors of pancreatic origin G3 according to WHO classification.&#xD;
&#xD;
          -  Patients who received 3 or more lines of systemic treatment.&#xD;
&#xD;
          -  Major surgery or trauma within 4 weeks prior to the first dose of sunitinib.&#xD;
&#xD;
          -  Radiation therapy or tumor embolization within 2 weeks prior to the first dose of&#xD;
             sunitinib.&#xD;
&#xD;
          -  Chemotherapy, immunotherapy, biologic therapy or investigational therapy within the&#xD;
             previous 2 weeks or 5 half-lives of the drug last received before the start of the&#xD;
             first dose of sunitinib treatment.&#xD;
&#xD;
          -  Prior treatment with high-dose chemotherapy that required hematopoietic rescue.&#xD;
&#xD;
          -  Immunosuppressive therapy or prolonged treatment with corticosteroids concomitantly&#xD;
             administered in the previous 3 months.&#xD;
&#xD;
          -  Resolution to grade &lt;2 (CTCAE according V4.03) of all previous related toxicities&#xD;
             except alopecia treatments.&#xD;
&#xD;
          -  Any ongoing toxicity from prior anti-cancer therapy that is &gt;Grade 1 (according CTCAE&#xD;
             V4.03) and/or that is progressing in severity, except alopecia.&#xD;
&#xD;
          -  Treatment with potent inhibitors or inducers of CYP3A4 or known to prolong the QT&#xD;
             interval in the previous 7 days.&#xD;
&#xD;
          -  Prior radiotherapy to more than 25% of the bone marrow - Presence of uncontrolled&#xD;
             metastatic brain disease, spinal cord compression, meningeal carcinomatosis or&#xD;
             leptomeningeal disease.&#xD;
&#xD;
          -  Any gastrointestinal malabsorption disorder or any other condition that, at&#xD;
             investigator's criteria, may affect the absorption of sunitinib or increase the risk&#xD;
             of bleeding or perforation.&#xD;
&#xD;
          -  Presence of any non-healing wound or ulcer.&#xD;
&#xD;
          -  Grade III/IV diarrhea in the screening period.&#xD;
&#xD;
          -  Diagnosis of any second malignancy within the last 5 years, except for adequately&#xD;
             treated basal cell or squamous cell skin cancer, or in situ carcinoma of the cervix&#xD;
             uteri.&#xD;
&#xD;
          -  Clinically significant cardio/cerebrovascular disease in the 6 months prior to&#xD;
             treatment.&#xD;
&#xD;
          -  Cardiac arrhythmias (NCI CTCAE version 4.0 grade &gt;2), atrial fibrillation of any grade&#xD;
             that requires medical treatment.&#xD;
&#xD;
          -  Corrected QT interval (QTcF) &gt; 180 msec.&#xD;
&#xD;
          -  Active hemoptysis in the past 6 weeks.&#xD;
&#xD;
          -  Evidence of active bleeding or bleeding diathesis.&#xD;
&#xD;
          -  Presence of endobronchial lesions and/or lesions that infiltrate large vessels.&#xD;
&#xD;
          -  Current treatment with acenocoumarol at therapeutic doses.&#xD;
&#xD;
          -  Known HIV infection.&#xD;
&#xD;
          -  Presence of uncontrolled active infection.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Previous allergic reaction to components structurally similar to sunitinib or any of&#xD;
             the excipients.&#xD;
&#xD;
          -  Inability to discontinue any prohibited concomitant medication.&#xD;
&#xD;
          -  Any illness (medical or psychiatric) or reason, in the investigator's opinion, that&#xD;
             interferes with the patient's ability to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Grande</last_name>
    <role>Principal Investigator</role>
    <affiliation>MD Anderson Cancer Center MADRID</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Valle de Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia/San Sebastián</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario J.M. Morales Meseguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Regional Virgen Del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 16, 2016</study_first_submitted>
  <study_first_submitted_qc>March 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 21, 2016</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sunitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

